Business Context and Reporting Period
This Form 6-K filing by IM Cannabis Corp. covers the month of August 2026, specifically reporting on a definitive Share Purchase Agreement entered into on August 16, 2026. The Company, a foreign private issuer based in Israel, is divesting its European-focused assets through the sale of 100% of the equity interests of its subsidiary, I.M.C. Holdings Ltd. ("IMC Holdings"), to Slil.com Holding Ltd. ("Slil").
Key Financial Metrics and Transaction Details
- Transaction Consideration: The deal includes acknowledgment of a C$3,000,000 advance payment already received from Slil, plus Slil's assumption of certain liabilities related to IMC Holdings and remaining subsidiaries. The aggregate liability assumption is not expected to materially exceed C$9,400,000.
- Debt Restructuring: As a condition precedent to closing, IMC Holdings must complete a pre-closing reorganization. This involves transferring Israeli operations to the Company and repaying outstanding intercompany indebtedness of approximately C$10,000,000 to the Company as a capital contribution to IMC Holdings.
- Projected Equity Impact: Management expects the Transactions to result in an improvement of approximately C$3.0 million in shareholders' equity.
- Financial Statements: The filing references unaudited pro forma interim condensed statements of financial position as of June 30, 2026 (Exhibit 99.2), though specific revenue, profit, or cash flow figures for the period are not detailed in the text of this summary.
Material Changes and Strategic Shift
The primary material change is the strategic divestiture of European operations to streamline the corporate structure. Upon closing, IM Cannabis Corp. will retain its core Israeli medical cannabis operations and related subsidiaries, including I.M.C. Pharma Ltd., Rivoli Trade & Marketing Ltd., R.A. Yarok Pharm Ltd., Rosen High Way Ltd., and Focus Medical Herbs Ltd. The transaction is designed to reduce debt, improve working capital and cash flow, and allow the Company to focus resources exclusively on its Israeli business.
Guidance, Risks, and Contingencies
- Closing Conditions: The transaction is subject to customary conditions, including the completion of the pre-closing reorganization, receipt of a valid tax certificate from the Israel Tax Authority, and other required consents. If closing does not occur by September 30, 2026, the agreement may be terminated.
- Forward-Looking Statements: Management anticipates the deal will improve financial metrics, but these are forward-looking and subject to inherent risks.
- Key Risks: The filing highlights significant risks including regulatory compliance in a highly regulated industry, changes in governmental policies, potential failure to maintain Nasdaq listing requirements, and the impact of war and civil unrest in Eastern Europe and the Middle East (specifically the multi-front war in Israel). Additional risks include supply chain constraints, competition, and the inability to achieve sustainable profitability.
Investor Verification Checklist
- Verify the final closing date and whether the September 30, 2026, termination deadline is met.
- Confirm the receipt of the valid tax certificate from the Israel Tax Authority.
- Review the full text of the Share Purchase Agreement (Exhibit 10.1) for specific liability caps and adjustment mechanisms.
- Examine the unaudited pro forma financial statements (Exhibit 99.2) to understand the post-transaction balance sheet.
- Monitor the Company's ability to maintain Nasdaq Capital Market listing requirements following the asset sale.